EU approves new use for Pfizer's Enbrel and Roche's Avastin; sales surge for Arena's obesity drug Belviq;

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Story | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Novartis hangs 'For Sale' sign on U.S. plant as it prepares to close and sale facility and lay off 500. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. Report | Follow @CarlyHFierce

> Pfizer's ($PFE) Enbrel scored a European nod to treat a rare inflammatory joint disorder at early stages of the disease. Report

> Arena Pharmaceuticals ($ARNA) reported a 43% rise in second-quarter sales of its obesity drug Belviq as DTC ads and a beefed-up sales force gained momentum. Report (reg. req.)

> Sanofi ($SNY) tapped India's Emcure Pharmaceuticals to market its oncology drugs Taxotere, Jevtana, Fludara and Fasturtec in that country. Report

> It's official: Roche ($RHHBY) has won approval to market Avastin in Europe as a treatment for recurrent ovarian cancer resistant to platinum-based chemo. Release | Report

> Drugstore owner The Walgreen Co. ($WAG) will buy the 55% stake in U.K. retailer Alliance Boots that it does not own but has decided against moving its legal domicile to Europe in a tax inversion plan. Story (sub. req.)

> Cubist Pharmaceuticals ($CBST) has recalled vials of its antibiotic Cubicin after glass particles were found in some. Story

> U.S.-based generic drugmaker Alvogen says it will pay $187 million in cash for South Korea's Dream Pharma. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Home healthcare design considerations addressed in FDA final guidance. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Accenture create brain wave app for immobilized patients. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. Story | Follow @MichaelGFierce

@EmilyWFierce: Quick point-of-care devices could be the next "holy grail" in detecting infectious diseases like Ebola. More from NBC News | Follow @EmilyWFierce

> Wright expects profitability by yearend with ankle system launch. Article

> Scientist robot gets venture funding from Omega. Item

> Siemens and Cerner teaming up to develop new med tech as part of $1.3B deal. Report

Biotech News

@FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> Regeneron hits the gas on R&D, pouring cash into a blockbuster pipeline. More

> Auris pulls off a $56M IPO to bankroll its ear treatments. Report

> Sarepta leaps into Ebola spotlight with a shelved therapy. Story

> Cytori shares slammed as safety concerns halt stem cell trials. Article

Drug Delivery News

> BD launches AutoShield Duo pen for diabetics. Report

> BioDelivery Sciences International to add 80 patients to clinical trial of Clonidine Topical Gel. Item

> Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. Article

> Biodegradable film strip enabling 14 months of drug delivery prototyped by MIT team. Story

> Stentys ditches bare metal stents as customers move to drug-eluting versions. Article

Diagnostics News

> Johns Hopkins group scrutinizes possible biomarker for suicide risk. News

> Dx industry is cautious, wary and diplomatic in the face of FDA's push to regulate LDTs. Report

> MGC Diagnostics completes Belgian M&A deal with an eye on globalization. More

> Exosome Diagnostics replaces CEO and relocates as it preps for commercialization. Article

> OncoCyte rolls out massive trial for bladder cancer Dx. Story

Pharma Marketing News

> Third to market may still be a charm for Lilly, BI's new diabetes med Jardiance. More

> GSK relaunches COPD patient site with blockbuster sales on the line. Item

> The formularies are here! Brace yourselves for the 48 new exclusions. Report

> J&J Baby aims to turn ingredients scandal into sales with 'transparent' ad campaign. Story

> Teva eyes 'hard switch' to hit Copaxone goals if the soft sell isn't enough. Article

And Finally... A Wisconsin man was sentenced to a year in prison for making erectile dysfunction drugs in his home lab from active ingredients he bought from China. Story

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.